Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7858-7869

  White Al Habeeb, Nicole M A ^a,b   Ho, Linh T ^a,b   Olkhov Mitsel, Ekaterina ^a,b   Kron, Ken ^c   Pethe, Vaijayanti ^a   Lehman, Melanie ^d   Jovanovic, Lidija ^d   Fleshner, Neil ^c   van der Kwast, Theodorus ^b,e   Nelson, Colleen C ^d   Bapat, Bharati ^a,b,e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Biomarkers; DAC treatment; Demethylating agent treatment; DNA methylation; Epigenetics; Expression array; Prostate cancer; Tumor markers

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TRANSCRIPTOME; TUMOR MARKER;

ACTA1 GENE; ARTICLE; B4GALNT1 GENE; CANCER CELL LINE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DSC3 GENE; EPIGENETICS; FOXD2 GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENOME ANALYSIS; GLEASON SCORE; HOXB6 GENE; HOXD3 GENE; HOXD8 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MARKER GENE; NRIP3 GENE; PROSTATE CANCER; SIGNAL TRANSDUCTION; TBX15 GENE; TBX2 GENE; TBX3 GENE; TESC GENE; TFAP2B GENE; TGFB2 GENE; TRAF3 GENE; VAX1 GENE; GENETICS; POLYMERASE CHAIN REACTION; PROCEDURES; PROSTATE TUMOR;

CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84907482180     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2313     Document Type: Article

References (43)

1. Siegel R, Ma, J., Zou, Z. and Jemal, A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014; 64(1):9-29.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6):1079-1092.
3. Jeronimo C and Henrique R. Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett. 2014; 342(2):264-274.
4. Troyer DA, Mubiru J, Leach RJ and Naylor SL. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis. Dis Markers. 2004; 20(2):117-128.
5. Eden A, Gaudet F, Waghmare A and Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003; 300(5618):455.
6. Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-428.
7. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC and Cussenot O. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007; 13(6):1720-1725.
8. Ellinger J, Haan K, Heukamp LC, Kahl P, Buttner R, Muller SC, von Ruecker A and Bastian PJ. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate. 2008; 68(1):42-49.
9. Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J, Trust C, Wang Y and Green G. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol. 2011; 186(5):2101-2106.
10. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C and Weiss G. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol. 2007; 177(5):1753-1758.
11. Banez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G and Castanos-Velez E. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010; 184(1):149-156.
12. Molinari C, Casadio V, Foca F, Zingaretti C, Giannini M, Avanzolini A, Lucci E, Saragoni L, Passardi A, Amadori D, Calistri D and Zoli W. Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy? J Cell Physiol. 2013; 228(12):2343-2349.
13. van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG, den Dunnen WF, Tijssen C, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T and French PJ. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013; 19(19):5513-5522.
14. Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glockner S, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, et al. Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer. Clin Cancer Res. 2014.
15. Dietrich D, Jung M, Puetzer S, Leisse A, Holmes EE, Meller S, Uhl B, Schatz P, Ivascu C and Kristiansen G. Diagnostic and Prognostic Value of SHOX2 and SEPT9 DNA Methylation and Cytology in Benign, Paramalignant and Malignant Pleural Effusions. PLoS One. 2013; 8(12):e84225.
16. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH and Bapat B. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011; 129(10):2454-2462.
17. Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH and Bapat B. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest. 2010; 90(7):1060-1067.
18. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, Tos AG and Merletti F. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol. 2009; 27(19):3161-3168.
19. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D and Jeronimo C. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007; 13(20):6122-6129.
20. Syeed N, Syed Sameer A, Hamid A, Shah ZA, Afroze D, Rasool R and Siddiqi MA. Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep. 2010; 3(5):883-887.
21. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B and van der Kwast T. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res. 2012; 18(10):2896-2904.
22. Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A, Yau P, Virtanen C, Winegarden N, Cheng J, Gingeras T and Petronis A. Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res. 2006; 34(2):528-542.
23. Ashktorab H, Daremipouran M, Goel A, Varma S, Leavitt R, Sun X and Brim H. DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics. 2014; 9(4).
24. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH and Huang TH. Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr. 2002; 132(8 Suppl):2430S-2434S.
25. Ricketts CJ, Morris MR, Gentle D, Shuib S, Brown M, Clarke N, Wei W, Nathan P, Latif F and Maher ER. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics. 2013; 5(1):16.
26. Glossop JR, Nixon NB, Emes RD, Haworth KE, Packham JC, Dawes PT, Fryer AA, Mattey DL and Farrell WE. Epigenome-wide profiling identifies significant differences in DNA methylation between matched-pairs of T-and B-lymphocytes from healthy individuals. Epigenetics. 2013; 8(11):1188-1197.
27. Zeng J, Nagrajan HK and Yi SV. Fundamental diversity of human CpG islands at multiple biological levels. Epigenetics. 2014; 9(4).
28. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shchors K, Heine VM, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010; 466(7303):253-257.
29. Lorincz MC, Dickerson DR, Schmitt M and Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol. 2004; 11(11):1068-1075.
30. Gavery MR and Roberts SB. Predominant intragenic methylation is associated with gene expression characteristics in a bivalve mollusc. PeerJ. 2013; 1:e215.
31. Huang YZ, Zhan ZY, Sun YJ, Cao XK, Li MX, Wang J, Lan XY, Lei CZ, Zhang CL and Chen H. Intragenic DNA methylation status down-regulates bovine IGF2 gene expression in different developmental stages. Gene. 2014; 534(2):356-361.
32. Shenker N and Flanagan JM. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer. 2012; 106(2):248-253.
33. Carvalho RH, Hou J, Haberle V, Aerts J, Grosveld F, Lenhard B and Philipsen S. Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas. J Thorac Oncol. 2013; 8(5):562-573.
34. Putnik M, Zhao C, Gustafsson JA and Dahlman-Wright K. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2012; 426(1):26-32.
35. Pan J, Chen Y, Mo C, Wang D, Chen J, Mao X, Guo S, Zhuang J and Qiu S. Association of DSC3 mRNA Down-Regulation in Prostate Cancer with Promoter Hypermethylation and Poor Prognosis. PLoS One. 2014; 9(3):e92815.
36. Guerrero-Bosagna CM, Sabat P, Valdovinos FS, Valladares LE and Clark SJ. Epigenetic and phenotypic changes result from a continuous pre and post natal dietary exposure to phytoestrogens in an experimental population of mice. BMC Physiol. 2008; 8:17.
37. Kawamura YI, Toyota M, Kawashima R, Hagiwara T, Suzuki H, Imai K, Shinomura Y, Tokino T, Kannagi R and Dohi T. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology. 2008; 135(1):142-151 e143.
38. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T and Bapat B. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One. 2009; 4(3):e4830.
39. Sieh S, Taubenberger AV, Rizzi SC, Sadowski M, Lehman ML, Rockstroh A, An J, Clements JA, Nelson CC and Hutmacher DW. Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PLoS One. 2012; 7(9):e40217.
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.
41. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267-273.
42. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000; 28(8):E32.
43. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M and Laird PW. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005; 33(21):6823-6836.